BRCA2 and neoplasm: Representative graphs show the striking tumor regression of PDX 435.1A-Cx treated with talazoparib + carboplatin compared to the vehicle control, as expected given the loss of BRCA2 (Fig. 5b, Supplementary Fig 6b).